STOCK TITAN
  1. Home
  2. News
  3. BRGX
  4. BioRegenx, Inc. Engages Sichenzia Ross Ference Carmel LLP for Legal Representation in Connection with Planned Uplisting to National Stock Exchange

BioRegenx, Inc. Engages Sichenzia Ross Ference Carmel LLP for Legal Representation in Connection with Planned Uplisting to National Stock Exchange

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
BioRegenx (OTC Pink:BRGX), a health technology company focused on microvascular and metabolic health, has announced the engagement of Sichenzia Ross Ference Carmel LLP (SRFC) as legal counsel for its planned uplisting to a major national exchange like Nasdaq or NYSE American. The company views this as a strategic move to enhance shareholder value and attract institutional investors. CEO William Resides highlighted SRFC's expertise in securities law and regulatory compliance as crucial for meeting the stringent requirements of national exchanges. The company anticipates that the uplisting will improve stock liquidity and visibility while strengthening its position to attract strategic investors and growth capital.
BioRegenx (OTC Pink:BRGX), un'azienda tecnologica nel settore della salute focalizzata sulla microvascolatura e la salute metabolica, ha annunciato l'ingaggio di Sichenzia Ross Ference Carmel LLP (SRFC) come consulente legale per la prevista quotazione su un importante mercato nazionale come Nasdaq o NYSE American. L'azienda considera questa mossa strategica per aumentare il valore per gli azionisti e attrarre investitori istituzionali. Il CEO William Resides ha sottolineato l'esperienza di SRFC nel diritto dei titoli e nella conformità normativa come fondamentale per soddisfare i rigorosi requisiti delle borse nazionali. L'azienda prevede che la nuova quotazione migliorerà la liquidità e la visibilità delle azioni, rafforzando al contempo la sua posizione per attrarre investitori strategici e capitale per la crescita.
BioRegenx (OTC Pink:BRGX), una empresa de tecnología sanitaria enfocada en la salud microvascular y metabólica, ha anunciado la contratación de Sichenzia Ross Ference Carmel LLP (SRFC) como asesor legal para su planificada subida a un mercado nacional importante como Nasdaq o NYSE American. La empresa considera esta acción como un movimiento estratégico para aumentar el valor para los accionistas y atraer inversores institucionales. El CEO William Resides destacó la experiencia de SRFC en derecho de valores y cumplimiento normativo como clave para cumplir con los estrictos requisitos de los mercados nacionales. La empresa anticipa que la subida de nivel mejorará la liquidez y visibilidad de las acciones, además de fortalecer su posición para atraer inversores estratégicos y capital de crecimiento.
BioRegenx(OTC Pink:BRGX)는 미세혈관 및 대사 건강에 중점을 둔 헬스 테크놀로지 회사로서, 주요 국가 거래소인 Nasdaq 또는 NYSE American으로의 상장 이전을 위해 Sichenzia Ross Ference Carmel LLP (SRFC)를 법률 자문사로 선임했다고 발표했습니다. 회사는 이를 주주 가치 향상과 기관 투자자 유치를 위한 전략적 조치로 보고 있습니다. CEO 윌리엄 레사이즈는 SRFC의 증권법 및 규제 준수 전문성이 국가 거래소의 엄격한 요건 충족에 필수적이라고 강조했습니다. 회사는 이번 상장 이전이 주식 유동성과 가시성을 개선하고 전략적 투자자 및 성장 자본 유치에 있어 입지를 강화할 것으로 기대하고 있습니다.
BioRegenx (OTC Pink:BRGX), une entreprise de technologie de la santé axée sur la santé microvasculaire et métabolique, a annoncé l'engagement de Sichenzia Ross Ference Carmel LLP (SRFC) en tant que conseil juridique pour son projet de montée en bourse sur une grande bourse nationale telle que Nasdaq ou NYSE American. La société considère cette démarche comme une stratégie visant à accroître la valeur pour les actionnaires et à attirer des investisseurs institutionnels. Le PDG William Resides a souligné l'expertise de SRFC en droit des valeurs mobilières et en conformité réglementaire comme essentielle pour répondre aux exigences strictes des bourses nationales. La société anticipe que cette montée en bourse améliorera la liquidité et la visibilité des actions tout en renforçant sa position pour attirer des investisseurs stratégiques et des capitaux de croissance.
BioRegenx (OTC Pink:BRGX), ein Health-Tech-Unternehmen mit Fokus auf mikrovaskuläre und metabolische Gesundheit, hat die Beauftragung von Sichenzia Ross Ference Carmel LLP (SRFC) als Rechtsberater für die geplante Notierung an einer großen nationalen Börse wie Nasdaq oder NYSE American bekannt gegeben. Das Unternehmen betrachtet diesen Schritt als strategische Maßnahme zur Steigerung des Aktionärswerts und zur Gewinnung institutioneller Investoren. CEO William Resides hob die Expertise von SRFC im Wertpapierrecht und in der Einhaltung regulatorischer Anforderungen als entscheidend hervor, um die strengen Vorgaben der nationalen Börsen zu erfüllen. Das Unternehmen erwartet, dass die Notierung die Aktienliquidität und Sichtbarkeit verbessert und gleichzeitig die Position zur Gewinnung strategischer Investoren und Wachstumskapital stärkt.
Positive
  • Potential uplisting to major exchanges (Nasdaq/NYSE) could increase visibility and trading volume
  • Strategic move to attract institutional investors and growth capital
  • Engagement of experienced securities law firm indicates serious commitment to uplisting process
Negative
  • No guarantee of successful uplisting completion
  • Company will need to meet strict listing requirements and standards
  • Potential additional compliance costs associated with national exchange listing

CHATTANOOGA, TENNESSEE / ACCESS Newswire / May 13, 2025 / BioRegenx, Inc. ("BioRegenx" or the "Company") (OTC Pink:BRGX), a health technology company advancing microvascular and metabolic health through its portfolio of patented diagnostics and therapeutics, today announced that it has formally engaged Sichenzia Ross Ference Carmel LLP (SRFC), a leading national securities and corporate law firm, to provide legal counsel related to its planned uplisting to a senior national securities exchange such as the Nasdaq or NYSE American.

This engagement marks a significant milestone in BioRegenx's strategic path toward enhancing shareholder value and broadening access to the institutional investment community.

"We are pleased to partner with SRFC, a firm with deep experience in securities law and regulatory compliance," said William Resides, Chief Executive Officer of BioRegenx. "Their proven track record guiding companies through uplisting transactions is an essential component of our capital markets roadmap, and their expertise will be instrumental as we prepare to meet the rigorous legal and governance standards required by national exchanges."

The Company believes that uplisting to a national exchange will not only provide greater liquidity and visibility for its common stock but also strengthen its ability to attract strategic investors, institutional interest, and long-term growth capital.

About Sichenzia Ross Ference Carmel LLP

Sichenzia Ross Ference Carmel LLP (SRFC) is a full-service law firm nationally recognized for its work in corporate, securities, and litigation matters. SRFC represents public and private companies, broker-dealers, investment advisors, and other financial institutions in a broad range of transactional, regulatory, and litigation matters. The firm regularly advises clients on IPOs, uplistings, PIPEs, SPACs, mergers and acquisitions, and SEC compliance matters. SRFC's litigation and regulatory group is highly regarded for defending clients before the SEC, FINRA, and in federal and state courts.
For more information, please visit: https://www.srfc.law

About BioRegenx, Inc.

BioRegenx, Inc. (OTC: BRGX) is an emerging biotechnology and health innovation company dedicated to redefining health from the inside out. Through its portfolio of wholly owned subsidiaries-including Microvascular Health Solutions, LLC, NuLife Sciences, Inc., DocSun Biomedical Holdings, LLC, and Findit AI Connect, LLC-BioRegenx develops and delivers patented diagnostics, clinically validated nutraceuticals, and next-generation digital health technologies powered by artificial intelligence (AI) for predictive vital sign monitoring.

At the core of BioRegenx's mission is a commitment to advancing microvascular, metabolic, and cellular health-key foundations for the prevention and management of chronic disease. The company is actively executing a multi-phase strategy to commercialize its proprietary technologies, forge strategic partnerships, and create sustainable long-term value for its shareholders through science, innovation, and transparency.

To learn more, please visit: www.bioregenx.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions and statements regarding future events or results. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or developments to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include, but are not limited to, regulatory developments, market conditions, investor appetite, and the Company's ability to meet listing requirements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these statements, except as required by law.

Contact Information:
Investor Relations
Email: investors@bioregenx.com
Phone: 866-770-4067

SOURCE: BioRegenx, Inc.



View the original press release on ACCESS Newswire

FAQ

What is BioRegenx (BRGX) planning for its stock listing in 2025?

BioRegenx (BRGX) is planning to uplist from OTC Pink to a major national exchange like Nasdaq or NYSE American, and has engaged Sichenzia Ross Ference Carmel LLP as legal counsel for this process.

Why is BRGX stock planning to uplist to Nasdaq or NYSE American?

The company aims to enhance shareholder value, increase stock liquidity, improve visibility, and attract institutional investors and growth capital through the uplisting.

Which law firm is helping BRGX with its planned uplisting?

Sichenzia Ross Ference Carmel LLP (SRFC), a national securities and corporate law firm, has been engaged to provide legal counsel for the uplisting process.

What does BioRegenx (BRGX) company do?

BioRegenx is a health technology company that develops patented diagnostics and therapeutics focused on microvascular and metabolic health.
Stock BRGX logo
BioRegenx, Inc

OTC:BRGX

BRGX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BRGX Stock Data

236.07M